McDermott Will & Emery advised Osivax on the deal. Osivax, a biopharmaceutical company developing broad-spectrum vaccines against highly mutated infectious viruses, signed an exclusive license option...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here